West Pharmaceutical Services (WST) Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $46.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 31.27% year-over-year to $46.6 million; the TTM figure through Mar 2026 stood at $46.6 million (down 31.27% YoY), while the FY2025 annual figure was $39.2 million, down 46.67% from the prior year.
• Accumulated Expenses came in at $46.6 million for Q1 2026 at West Pharmaceutical Services, up from $39.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $111.8 million in Q3 2025 to a low of $39.2 million in Q4 2025.
• A 5-year average of $77.6 million and a median of $78.1 million in 2022 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 40.45% in 2025 and fell as far as 46.67% in 2025.
• West Pharmaceutical Services' Accumulated Expenses stood at $76.8 million in 2022, then surged by 37.89% to $105.9 million in 2023, then plunged by 30.59% to $73.5 million in 2024, then slumped by 46.67% to $39.2 million in 2025, then climbed by 18.88% to $46.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $46.6 million, $39.2 million, and $111.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison